Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Oncology Right
  3. Retevmo (selpercatinib) tablets Right
  4. What are the approved indications for Retevmo® (selpercatinib)?
Search Retevmo (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Retevmo ® (selpercatinib) tablets

40 mg, 80 mg, 120 mg, 160 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What are the approved indications for Retevmo® (selpercatinib)?

Selpercatinib is approved in the United States in adults with RET fusion-positive NSCLC and in patients 2 years of age and older with RET-mutant MTC, RET fusion-positive thyroid cancer and RET fusion-positive solid tumors.

US_cFAQ_SEL100_FDA_APPROVAL
US_cFAQ_SEL100_FDA_APPROVALen-US

Selpercatinib Approved Indications in the United States

Selpercatinib is a kinase inhibitor approved by the Food and Drug Administration (FDA) for the treatment of 

  • adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test
  • adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy
  • adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate), and
  • adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.*1

    *The indication for solid tumors is approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trial(s).1

    Selpercatinib Approved Formulations in the United States

    On April 10, 2024, the FDA approved a new tablet dosage form of selpercatinib.2 Selpercatinib tablets will be available in 40mg, 80mg, 120mg, and 160mg strengths in the second half of 2024.1

    Selpercatinib capsules will be available until the tablet transition is complete. Once the transition is complete, capsules will no longer be available. 

    Enclosed Prescribing Information

    RETEVMO® (selpercatinib) capsules and tablets, for oral use, Lilly

    References

    1Retevmo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.

    2Drugs@FDA: FDA Approved Drug Products. Retevmo® (selpercatinib). New Drug Application number: 213246. Accessed April 10, 2024. http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213246

    Date of Last Review: September 30, 2024

    Are you satisfied with this content?

    Can't find what you're looking for? Contact us for answers to your medical questions.

    • Copyright
    • Terms of Use
    • Privacy Statement
    • Consumer Health Privacy Notice
    • Accessibility Statement
    • Sitemap

      This site is intended for US Healthcare Professionals only.

      4.0.44 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

      Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

      California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
      Cookie Settings
      facebook twitter linkedin
      visit www.phactmi.org
      Lilly